Clinical Trials
445
Active:11
Completed:71
Trial Phases
6 Phases
Early Phase 1:11
Phase 1:25
Phase 2:103
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (335 trials with phase data)• Click on a phase to view related trials
Not Applicable
149 (44.5%)Phase 2
103 (30.7%)Phase 4
28 (8.4%)Phase 1
25 (7.5%)Phase 3
19 (5.7%)Early Phase 1
11 (3.3%)RN1201 Injection for Autoimmune Diseases Refractory to Standard Therapies
Not Applicable
Not yet recruiting
- Conditions
- Autoimmune Diseases Refractory to Standard Therapies
- Interventions
- Biological: allogeneic CAR-T
- First Posted Date
- 2025-08-06
- Last Posted Date
- 2025-08-06
- Target Recruit Count
- 18
- Registration Number
- NCT07105735
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
A Study of GD007 (Human iPSC-Exosome Liquid Dressing) for Safety and Dose-Finding in Moderate-Severe Intrauterine Adhesions
Not Applicable
- Conditions
- Moderate-Severe Intrauterine Adhesions
- Interventions
- Drug: GD007 Low-dose drug groupDrug: GD007 Mid-dose drug groupDrug: GD007 High-dose drug groupDrug: GD007 Blank Control drug Group
- First Posted Date
- 2025-08-03
- Last Posted Date
- 2025-08-03
- Target Recruit Count
- 29
- Registration Number
- NCT07101484
- Locations
- 🇨🇳
Clinical Center o Reproductive Medicine of First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Efficacy of Auricular Acupuncture Therapy in the Prevention of CIPN in Breast Cancer
Not Applicable
Recruiting
- Conditions
- Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer
- First Posted Date
- 2025-07-29
- Last Posted Date
- 2025-07-29
- Target Recruit Count
- 110
- Registration Number
- NCT07092111
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
Not Applicable
Recruiting
- Conditions
- HER2 + Breast Cancer
- Interventions
- First Posted Date
- 2025-07-15
- Last Posted Date
- 2025-07-15
- Target Recruit Count
- 74
- Registration Number
- NCT07065435
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Efficacy and Safety of Minimally Invasive D2+PAND Gastrectomy for Gastric Cancer With PAN Metastasis After Conversion Immunochemotherapy
Not Applicable
Recruiting
- Conditions
- Gastric Cancer
- First Posted Date
- 2025-07-09
- Last Posted Date
- 2025-07-09
- Target Recruit Count
- 30
- Registration Number
- NCT07056010
- Locations
- 🇨🇳
First Affiliated Hospital of Nanjing Medical Unviersity, Nanjing, Jiangsu, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 89
- Next
News
No news found